Coherus Bio (CHRS) Stock Price, Quote & News

Company Profile

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investi...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 649 3530

Website: www.coherus.com

Address:

333 Twin Dolphin Drive, Suite 600, Redwood City, United States

Sven_Bonn Aug. 19 at 12:59 PM

$CHRS Why J&J could fit strategically Coherus owns the worldwide rights to casdozokitug and tagmokitug and has explicitly discussed potential ex-US licensing transactions if the clinical data support them. That creates several possible paths: Scenario My view J&J licenses tagmokitug Very logical given the existing collaboration J&J licenses casdozokitug Plausible if October HCC data are strong J&J licenses both drugs Strategically interesting J&J acquires Coherus entirely Possible, but much more speculative The tagmokitug relationship is especially relevant because J&J is already gaining scientific and operational exposure to one of Coherus's major pipeline assets. Why the CVR timing is interesting This connects with our previous discussion. Coherus is separating the legacy biosimilar assets through the new CVRs just before the major oncology catalysts. After that separation, a potential strategic buyer would essentially be looking at a much cleaner company: LOQTORZI + casdozokitug + tagmokitug + oncology infrastructure rather than having to value and negotiate around old biosimilar patents, cell lines and royalty streams. That doesn't prove that Coherus is preparing itself for sale. But it does make a future transaction structurally cleaner. What argues against the J&J takeover theory The existing agreement is specifically a clinical collaboration involving tagmokitug and pasritamig. The agreement also makes clear that J&J and Coherus retain their respective commercial rights. I have found no SEC filing indicating that J&J is negotiating to acquire Coherus, and no evidence that J&J currently has rights to casdozokitug. So I would distinguish carefully between: Fact: J&J already has a direct clinical relationship with Coherus. Reasonable inference: J&J could become interested in a deeper tagmokitug relationship if the data are good. Speculation: J&J could license casdozokitug or acquire Coherus.

0 · Reply

Mirbo63 Aug. 19 at 11:28 AM

$CHRS Many of you including myself have never seen short interest in our stock go down to fumes. We are going to watch that happen in the next month. Those shorts that fail to realize that having to deliver a “value” attributed to a CVR which is both complex and problematic will figure it out the hard way. Not to mention the data cards that are about to be turned over so after that. A perfect storm is a brewing “Leave Pompeii”!

0 · Reply

Sven_Bonn Aug. 19 at 11:16 AM

$CHRS CVR separation → Casdozokitug data. If Coherus simply needed every available dollar, the obvious strategy would have been: Sell remaining biosimilar assets → keep perhaps $20–50M+ inside Coherus → use it to finance oncology development. Instead, Coherus is effectively assigning the economic value of those legacy assets to existing shareholders through the CVRs. After the CVR distribution, the investment story becomes much cleaner: LOQTORZI + Casdozokitug + Tagmokitug + oncology pipeline rather than: Oncology + old biosimilar patents + cell lines + Pfizer royalties + other legacy assets. Then come the Casdozokitug data This is where the strategic logic gets interesting. Coherus has described its strategy as “Drugs, Data and Deals” and has specifically discussed ex-US licensing opportunities for Casdozokitug and Tagmokitug. If the October Casdozokitug data are strong, one logical sequence could therefore be: Strong Phase 2 data → ex-US partnership → significant upfront payment → partner helps finance further development. An even more bullish scenario would be: Exceptional data → increased Big Pharma interest → partnership, strategic investment, or potentially acquisition interest. That could provide one explanation for why Coherus is willing to give the legacy biosimilar economics to shareholders rather than keeping that cash inside the company.

0 · Reply

HansDampf1 Aug. 19 at 4:58 AM

$CHRS REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) ("Coherus", "Coherus Oncology" or the "Company") today announced a special dividend of contingent value rights (each, a "CVR" and collectively, the "CVRs"), which will be distributed on a pro rata basis to stockholders of record of the Company's common stock as of 5:00 p.m., New York City time, on September 30, 2026 (the "Record Date"). The distribution date for the CVRs (the "Distribution Date") will be October 7, 2026. https://www.finanznachrichten.de/nachrichten-2026-08/69337740-coherus-oncology-inc-coherus-oncology-announces-special-dividend-of-biosimilar-contingent-value-rights-399.htm

0 · Reply

cpe1973 Aug. 18 at 9:16 PM

$CHRS I hope everyone is doing what I did today, made sure all of my brokerage accounts have stock lending turned off for CHRS.

2 · Reply

simonig1 Aug. 18 at 8:39 PM

$CHRS The shorts with ~28 million short shares will be required to DELIVER ~28 million CVRs if they stay short on or after Sept. 30th. It looks like they will be buying back their short shares by Sept. 30th to avoid delivery of these CVRs. This is very Bullish for the stock leading into that date!!! IMHO. ;-0)

0 · Reply

Cowpokecaleb Aug. 18 at 7:56 PM

$CHRS I heard they struck oil in the CHRS parking lot

2 · Reply

Jack_Nicholson_Truth Aug. 18 at 7:55 PM

$CHRS same scammer troll. Tell us more about your 5 shares bro

1 · Reply

Toadvind Aug. 18 at 7:52 PM

$CHRS I have sold my long position and am 100% short. GLTA

3 · Reply

Zephix Aug. 18 at 7:08 PM

$CHRS on close watch

0 · Reply

Coherus Oncology issuing special dividend of biosimilar contingent value rights

Aug 17, 2026, 5:33 PM EDT - 1 day ago

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

2026-08-07T11:46:55.000Z - 12 days ago

Coherus Oncology price target lowered to $10 from $12 at Guggenheim

2026-08-05T22:40:15.000Z - 13 days ago

Coherus Oncology reports Q2 EPS (19c), consensus (12c)

Aug 5, 2026, 5:00 PM EDT - 13 days ago

Coherus Oncology Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 13 days ago

Coherus Oncology Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 13 days ago

Coherus Oncology Quarterly report: Q2 2026

Aug 5, 2026, 4:28 PM EDT - 13 days ago

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

Jul 22, 2026, 1:36 PM EDT - 27 days ago

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

2026-06-23T19:19:59.000Z - 2 months ago

Coherus, Zumutor collaborate for ZM008, Loqtorzi combination study

Jun 23, 2026, 2:00 PM EDT - 2 months ago

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

Jun 4, 2026, 9:55 AM EDT - 2 months ago

Coherus Oncology Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 8:00 AM EDT - 2 months ago

Coherus Oncology Proxy statement: Proxy filing

May 27, 2026, 4:30 PM EDT - 2 months ago

Coherus Oncology Transcript: AGM 2026

2026-05-11T23:20:35.000Z - 3 months ago

Coherus Oncology reports Q1 EPS (28c), consensus (26c)

May 11, 2026, 5:00 PM EDT - 3 months ago

Coherus Oncology Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

Coherus Oncology Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

Coherus Oncology Quarterly report: Q1 2026

May 11, 2026, 4:05 PM EDT - 3 months ago

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

2026-05-11T12:37:08.000Z - 3 months ago

Guggenheim starts Coherus with Buy on anti-tumor potential

2026-05-11T10:36:08.000Z - 3 months ago

Coherus Oncology initiated with a Buy at Guggenheim

May 5, 2026, 8:00 AM EDT - 3 months ago

Coherus Oncology Proxy statement: Proxy filing

May 4, 2026, 9:30 AM EDT - 3 months ago

Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Coherus Oncology Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 4 months ago

Coherus Oncology Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 4 months ago

Coherus Oncology Proxy statement: Proxy filing

Mar 10, 2026, 2:50 PM EDT - 5 months ago

Coherus Oncology Transcript: The Citizens Life Sciences Conference 2026

2026-03-09T20:40:57.000Z - 5 months ago

Coherus Oncology reports Q4 EPS (34c), consensus (31c)

Mar 9, 2026, 4:30 PM EDT - 5 months ago

Coherus Oncology Earnings Call Transcript: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 5 months ago

Coherus Oncology Annual report: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 5 months ago

Coherus Oncology Earnings release: Q4 2025

Mar 9, 2026, 4:15 PM EDT - 5 months ago

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

Mar 4, 2026, 11:50 AM EST - 5 months ago

Coherus Oncology Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:30 AM EST - 6 months ago

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

Feb 23, 2026, 9:30 AM EST - 6 months ago

Coherus Oncology to Participate in Upcoming Investor Conferences

Feb 17, 2026, 4:11 PM EST - 6 months ago

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

2026-02-13T11:50:56.000Z - 6 months ago

Coherus Oncology 28.6M share Spot Secondary priced at $1.75

Feb 12, 2026, 9:18 PM EST - 6 months ago

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

2026-02-12T21:12:06.000Z - 6 months ago

Coherus Oncology announces common stock offering, no amount given

2026-01-22T21:16:58.000Z - 7 months ago

Coherus Oncology initiated with an Outperform at Oppenheimer ahead of readouts

2026-01-22T21:11:03.000Z - 7 months ago

Coherus Oncology initiated with an Outperform at Oppenheimer

Jan 13, 2026, 1:30 PM EST - 7 months ago

Coherus Oncology Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 1:30 PM EST - 7 months ago

Coherus Oncology Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 9:30 AM EST - 8 months ago

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

2026-01-05T14:51:47.000Z - 8 months ago

Coherus Oncology announces publication highlighting CCR8 antibody tagmokitug

Jan 5, 2026, 9:30 AM EST - 8 months ago

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

Dec 17, 2025, 1:30 PM EST - 8 months ago

Coherus Oncology Transcript: Biotech Discovery Series

2025-12-08T13:45:59.000Z - 9 months ago

Coherus Oncology announces six-year OS results from Phase 3 JUPITER-02 trial

Dec 8, 2025, 8:30 AM EST - 9 months ago

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Nov 18, 2025, 5:30 AM EST - 9 months ago

Coherus Oncology Transcript: Jefferies London Healthcare Conference 2025

2025-11-13T22:35:29.000Z - 9 months ago

Coherus Oncology files $150M mixed securities shelf

Nov 13, 2025, 7:00 AM EST - 9 months ago

Coherus Oncology Registration statement: Registration Filing

Nov 10, 2025, 1:15 PM EST - 10 months ago

Coherus Oncology Transcript: UBS Global Healthcare Conference 2025

Nov 7, 2025, 9:00 AM EST - 10 months ago

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Nov 6, 2025, 5:00 PM EST - 10 months ago

Coherus Oncology Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

Coherus Oncology Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

Coherus Oncology Earnings release: Q3 2025

Nov 6, 2025, 4:14 PM EST - 10 months ago

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 1:54 PM EST - 10 months ago

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

Oct 30, 2025, 8:30 AM EDT - 10 months ago

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 3, 2025, 9:05 AM EDT - 11 months ago

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 1, 2025, 1:00 PM EDT - 11 months ago

Coherus Oncology Transcript: UBS Virtual Oncology Day

Sep 10, 2025, 11:00 AM EDT - 1 year ago

Coherus Oncology Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 1:25 PM EDT - 1 year ago

Coherus Oncology Transcript: Baird Global Healthcare Conference 2025

2025-09-04T11:35:24.000Z - 1 year ago

Coherus Biosciences upgraded to Buy from Neutral at Roth Capital

2025-09-04T11:35:13.000Z - 1 year ago

Coherus Biosciences upgraded to Buy from Hold at Maxim

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings release: Q2 2025

Aug 7, 2025, 4:41 PM EDT - 1 year ago

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 4:45 PM EDT - 1 year ago

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Coherus Oncology Slides: Corporate Presentation

Jun 4, 2025, 5:30 PM EDT - 1 year ago

Coherus Oncology Transcript: Jefferies Global Healthcare Conference 2025

May 27, 2025, 3:00 PM EDT - 1 year ago

Coherus Oncology Transcript: 6th Annual Oncology Innovation Summit

May 20, 2025, 12:00 PM EDT - 1 year ago

Coherus Oncology Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings Call Transcript: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Quarterly report: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings release: Q1 2025

May 12, 2025, 4:15 PM EDT - 1 year ago

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 9:00 AM EDT - 1 year ago

Coherus Oncology Transcript: The Citizens JMP Life Sciences Conference 2025

May 5, 2025, 4:01 PM EDT - 1 year ago

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

May 1, 2025, 5:04 PM EDT - 1 year ago

Coherus to Participate in Upcoming Investor Conferences

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Coherus Oncology Transcript: KOL Event

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Coherus Oncology Press release: KOL Event

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Coherus Oncology Slides: KOL Event

Apr 28, 2025, 10:10 AM EDT - 1 year ago

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 10, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings Call Transcript: Q4 2024

Mar 10, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Annual report: Q4 2024

Mar 10, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings release: Q4 2024

Mar 10, 2025, 4:12 PM EDT - 1 year ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

Mar 4, 2025, 11:50 AM EST - 1 year ago

Coherus Oncology Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Mar 3, 2025, 8:30 AM EST - 1 year ago

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

Feb 24, 2025, 9:08 AM EST - 1 year ago

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Jan 28, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Jan 14, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Jan 14, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Jan 13, 2025, 8:15 PM EST - 1 year ago

Coherus Oncology Transcript: at 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 8:15 PM EST - 1 year ago

Coherus Oncology Slides: FY 2025

Dec 18, 2024, 8:30 AM EST - 1 year ago

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Dec 4, 2024, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Dec 4, 2024, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Dec 3, 2024, 3:15 PM EST - 1 year ago

Coherus Oncology Transcript: Citi's 2024 Global Healthcare Conference

Dec 3, 2024, 8:00 AM EST - 1 year ago

Coherus Oncology Transcript: Status Update

Dec 3, 2024, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Dec 3, 2024, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Nov 27, 2024, 4:01 PM EST - 1 year ago

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

Nov 6, 2024, 5:00 PM EST - 1 year ago

Coherus Oncology Earnings Call Transcript: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Coherus Oncology Quarterly report: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Coherus Oncology Earnings release: Q3 2024

Nov 6, 2024, 4:01 PM EST - 1 year ago

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 4:20 PM EDT - 1 year ago

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings Call Transcript: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Quarterly report: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings release: Q2 2024

Aug 1, 2024, 9:00 AM EDT - 2 years ago

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Jun 27, 2024, 8:26 AM EDT - 2 years ago

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

Jun 6, 2024, 8:30 AM EDT - 2 years ago

Coherus Oncology Transcript: Jefferies 2024 Global Healthcare Conference

May 30, 2024, 9:00 AM EDT - 2 years ago

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

May 29, 2024, 12:00 PM EDT - 2 years ago

Coherus Oncology Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

May 23, 2024, 5:51 PM EDT - 2 years ago

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024, 9:00 AM EDT - 2 years ago

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

May 13, 2024, 8:00 AM EDT - 2 years ago

Coherus Oncology Proxy statement: Proxy Filing

May 9, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings Call Transcript: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Quarterly report: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings release: Q1 2024

May 9, 2024, 4:01 PM EDT - 2 years ago

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 7:30 AM EDT - 2 years ago

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

May 8, 2024, 9:00 AM EDT - 2 years ago

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

May 1, 2024, 4:30 PM EDT - 2 years ago

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 24, 2024, 10:02 AM EDT - 2 years ago

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Coherus Oncology Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Coherus Oncology Proxy statement: Proxy Filing

Apr 8, 2024, 8:30 AM EDT - 2 years ago

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

Mar 13, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings Call Transcript: Q4 2023

Mar 13, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Annual report: Q4 2023

Mar 13, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings release: Q4 2023

Mar 13, 2024, 4:01 PM EDT - 2 years ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

Mar 5, 2024, 4:01 PM EST - 2 years ago

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

Mar 4, 2024, 1:00 AM EST - 2 years ago

Coherus Completes Divestiture of Ophthalmology Franchise

Feb 23, 2024, 5:33 PM EST - 2 years ago

Coherus BioSciences Announces New Employment Inducement Grants

Feb 21, 2024, 8:30 AM EST - 2 years ago

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Sven_Bonn Aug. 19 at 12:59 PM

0 · Reply

Mirbo63 Aug. 19 at 11:28 AM

0 · Reply

Sven_Bonn Aug. 19 at 11:16 AM

0 · Reply

HansDampf1 Aug. 19 at 4:58 AM

0 · Reply

cpe1973 Aug. 18 at 9:16 PM

$CHRS I hope everyone is doing what I did today, made sure all of my brokerage accounts have stock lending turned off for CHRS.

2 · Reply

simonig1 Aug. 18 at 8:39 PM

0 · Reply

Cowpokecaleb Aug. 18 at 7:56 PM

$CHRS I heard they struck oil in the CHRS parking lot

2 · Reply

Jack_Nicholson_Truth Aug. 18 at 7:55 PM

$CHRS same scammer troll. Tell us more about your 5 shares bro

1 · Reply

Toadvind Aug. 18 at 7:52 PM

$CHRS I have sold my long position and am 100% short. GLTA

3 · Reply

Zephix Aug. 18 at 7:08 PM

$CHRS on close watch

0 · Reply

xxxjackstonerxxx Aug. 18 at 6:53 PM

$CHRS just going back to 1.44 so it can chill there for another few months

0 · Reply

Jack_Nicholson_Truth Aug. 18 at 4:07 PM

$CHRS Chad Lawton aka Bigdaddy aka Samisphere aka vsingh aka TROLL BOTS. Don't trust anything on stocktwits people!

1 · Reply

Jack_Nicholson_Truth Aug. 18 at 4:05 PM

$CHRS I love when troll bots repost themselves and comment on their fake troll cellphone farm. Remember when they ALL POSTED CHRS WOULD GO BANKRUPT yesterday?

0 · Reply

whateverhappenedthere Aug. 18 at 3:58 PM

$CHRS

1 · Reply

Henry20feb_ Aug. 18 at 3:56 PM

$CHRS Debt risk reduced: Coherus refinances expensive near-term debt and pushes maturity out to 2031. More financial flexibility: $55M facility now, with access to up to another $45M if conditions are met. Cleaner CHRS story: Coherus becomes a focused immuno-oncology company without the remaining biosimilar baggage. Old assets aren't given away: shareholders keep the potential value of the legacy biosimilar assets through the CVR. 1 CHRS share = 1 CVR for eligible shareholders on the September 30 record date. Potential extra value: CVR holders receive their pro-rata share of net proceeds if the legacy assets are monetized before October 2028. Bottom line: cleaner balance sheet + clearer oncology focus + potential CVR bonus = a modest but clearly positive development for CHRS shareholders. (Thanks to AI)

0 · Reply

Grandgustav Aug. 18 at 3:34 PM

$CHRS

0 · Reply

Toadvind Aug. 18 at 3:28 PM

$CHRS

1 · Reply

vsingh120582 Aug. 18 at 3:27 PM

$CHRS I see this as clean up effort on +ve note. SURF SVR has not yield anything to holders. If there is biosimilar/add associated IP sitting in their labs...(with more FDA flexibility)...could mean some monetization..

1 · Reply

Samishere Aug. 18 at 3:13 PM

$CHRS CVR’s mean literally nothing!

0 · Reply

Fomoninja Aug. 18 at 3:06 PM

$CHRS I wouldn't be surprised if we got some insider action before Sep 30. 🚀🚀🚀

0 · Reply

Zephix Aug. 18 at 2:53 PM

$CHRS

0 · Reply

Samishere Aug. 18 at 2:43 PM

$CHRS Good gawd, the finagling shyster moves by this ceo are , admittedly, exceptional! He is a financial scam artist of the highest order! You’re going to get hosed again bags! You’ve bern warned!

1 · Reply

Market Cap	90.31M
Revenue (ttm)	266.96M
Net Income (ttm)	28.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	10.68%
Debt to Equity Ratio	-0.20

Volume	1,822,400
Avg Vol	1,708,078
Day's Range	N/A - N/A
Shares Out	115.93M
Stochastic %K	30%
Beta	1.01
Analysts	Strong Sell
Price Target	$5.26